💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Asunaprevir

CHEMBL2105735 Phase 4 Onaylandı Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
748.3 g/mol
LogP
4.9
Phase
4

An NS3/4A protease inhibitor that blocks a key enzyme hepatitis C virus needs to process its proteins and replicate, used in combination with other direct-acting antivirals for chronic HCV infection.

Moleküler Ağırlık

748,3000 g/mol

LogP

4,90

TPSA

191,00 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Hepatitis C

Etki Mekanizması

Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1

                

                

                
                

                    
InChI

                    
InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C35H46ClN5O9S

                    

                    
                    

                        
HBD / HBA

                        
3 / 10

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
14

                    

                    
                    
                    

                        
Ağır Atomlar

                        
51

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
An NS3/4A protease inhibitor that blocks a key enzyme hepatitis C virus needs to process its proteins and replicate, used in combination with other direct-acting antivirals for chronic HCV infection.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral protease enzymes required for the cleavage of polyprotein precursors into functional viral proteins, blocking viral maturation and replication.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Asunaprevir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2105735.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 16076883.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.